Dark

SABS
SAB Biotherapeutics, Inc. Common Stock
stock NASDAQ

At Close

May 16, 2025 12:01:30 PM EDT

1.87USD-3.608%(-0.07)28,466

0.00Bid 0.00Ask 0.00Spread

Pre-market

Dec 31, 1969 7:00:00 PM EST

0.00USD-100.000%(-1.94)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 24, 2022

09:26AM EST On Positive Virology Data, SAB Biotherapeutics' COVID-19 Drug To Move To Phase 3 In NIH ACTIV-2 Trial Benzinga

06:33AM EST SAB Biotherapeutics, Inc. (SABS), a clinical-stage, biopharmaceutical company focused on human polyclonal antibodies, reported Monday positive Phase 2 safety and efficacy data of SAB-185. RTTNews

06:08AM EST SAB Biotherapeutics Reports Positive Clinical Results From NIH ACTIV-2 COVID Trial RTTNews

06:05AM EST SAB Biotherapeutics Reports Phase 2 Virology Data Demonstrating SAB-185 Met Criteria For Advancement To Phase 3 In NIH ACTIV-2 Trial For Treatment Of COVID-19; Co. Reports 'SAB-185 was safe and well-tolerated at both doses tested in Phase 2' Benzinga

06:00AM EST SAB-185 is being evaluated in Phase 3 NIH-Sponsored ACTIV-2 COVID trial of high-risk patients following positive DSMB review of interim Phase 2 safety and efficacy data in September GlobeNewswire Inc

Jan 5, 2022

07:00AM EST SAB Biotherapeutics to Present at 2022 H.C. Wainwright BioConnect GlobeNewswire Inc

Dec 20, 2021

06:08AM EST SAB Biotherapeutics Added To NASDAQ Biotechnology Index Benzinga

Dec 16, 2021

08:20AM EST The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street Benzinga

06:49AM EST SAB Biotherapeutics (SABS), said on Thursday that its therapeutic candidate -SAB-185 for the treatment of Covid-19 infections, retained neutralization impact against the Omicron SARS-CoV-2 variant in an in vitro pseudovirus model. RTTNews

06:11AM EST SAB Biotherapeutics Says SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro RTTNews

06:04AM EST SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro Benzinga

06:00AM EST FDA laboratory testing confirms SAB-185 neutralizes Omicronand other variants of concern with in vitro pseudovirus model GlobeNewswire Inc

Dec 1, 2021

08:41AM EST The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case Benzinga

08:36AM EST The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment, Regulatory Setbacks For CTI Biopharma, Favorable Ruling For BioXcel, Viatris In Tecfidera Patent Case Benzinga

08:12AM EST SAB Biotherapeutics (SABS) said SAB-176, the company's investigational therapeutic for the treatment of seasonal influenza, achieved statistically significant reductions in viral load and clinical signs and symptoms compared to placebo in a phase 2a challenge study. RTTNews

07:43AM EST SAB Biotherapeutics Shares Now Trading Lower After Co Announced its Influenza Study Met Its Primary Endpoint Benzinga

07:38AM EST SAB Biotherapeutics Announces SAB-176 Meets Primary Endpoint In Phase 2a Challenge Study RTTNews

07:09AM EST SAB Biotherapeutics Announces SAB-176 Met Its Primary Endpoint In Phase 2a Challenge Study In Adults Infected With Influenza Virus Benzinga

07:00AM EST Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated GlobeNewswire Inc

Nov 30, 2021

07:52PM EST Pomerantz LLP is investigating claims on behalf of investors of SAB Biotherapeutics, Inc. (SAB or the Company) (NASDAQ:SABS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Nov 22, 2021

07:00AM EST Advanced SAB-185 to Phase 3 in NIH-Sponsored ACTIV-2 Trial for treatment of COVID-19 following positive DSMB recommendation at interim analysis GlobeNewswire Inc

Nov 5, 2021

10:07AM EDT Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021 Benzinga

09:45AM EDT Chardan Capital Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $17 Benzinga

Nov 2, 2021

11:11AM EDT Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2021 Benzinga

10:54AM EDT The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US Benzinga

10:42AM EDT Baird Initiates Coverage On SAB Biotherapeutics with Outperform Rating, Announces Price Target of $23 Benzinga

06:16AM EDT The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 05.55 A.M. EDT). RTTNews

.dark-mode .mG7WNh{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .mG7WNh{ color: #333333; background-color: white; border: 2px solid #333333; }SABSSAB Biotherapeutics, Inc. Common Stockstock NASDAQ

SABS
SAB Biotherapeutics, Inc. Common Stock
stock NASDAQ